Intravenous recombinant tissue plasminogen activator administered after 3 h following onset of ischaemic stroke: A metaanalysis

International Journal of Stroke

Volumn 6, Issue 1, 2011, Pages 25-32

  Maiser, Samuel J ^a   Georgiadis, Alexandros L ^a   Suri, M Fareed K ^a   Vazquez, Gabriela ^a   Lakshminarayan, Kamakshi ^a   Qureshi, Adnan I ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

3 h; Acute; Intravenous; RtPA; Stroke; Therapy

Indexed keywords

ALTEPLASE; PLACEBO;

ADULT; AGED; ARTICLE; BIOSIS; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; INFORMATION RETRIEVAL; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; MEDICAL RECORD; MEDLINE; MORTALITY; NEUROLOGIC EXAMINATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; RISK; STATISTICAL MODEL; SYMPTOM; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PLASMINOGEN ACTIVATORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650970741     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2010.00537.x     Document Type: Article

References (27)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581-7.
2. Adams HP Jr, del Zoppo G, Alberts MJ et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 2007; 115:e478-534.
3. European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25:457-507.
4. Chung H, Refoios Camejo R, Barnett D. Alteplase for the treatment of acute ischaemic stroke: NICE technology appraisal guidance. Heart 2007; 93:1616-7.
5. Hacke W, Kaste M, Fieschi C et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352:1245-51.
6. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 h after symptom onset. The ATLANTIS study: a randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA 1999; 282:2019-26.
7. Davis SM, Donnan GA, Parsons MW et al. Effects of alteplase beyond 3 h after stroke in the echoplanar imaging thrombolytic evaluation trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008; 7:299-309.
8. Hacke W, Kaste M, Bluhmki E et al. Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke. N Engl J Med 2008; 359:1317-29.
9. Hacke W, Donnan G, Fieschi C et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363:768-74.
10. Sandercock P, Lindley R, Wardlaw J et al. The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke. Trials 2008; 9:15-7.
11. Wahlgren N, Ahmed N, Davalos A et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008; 372:1303-9.
12. Brott TG, Haley EC Jr, Levy DE et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 min. Stroke 1992; 23:632-40.
13. Mori E, Yoneda Y, Tabuchi M et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42:976-82.
14. Normand SL. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 1999; 18:321-59.
15. Schmid JE, Koch GG, LaVange LM. An overview of statistical issues and methods of meta-analysis. J Biopharm Stat 1991; 1:103-20.
16. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539-58.
17. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56:455-63.
18. Hacke W, Kaste M, Fieschi C et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274:1017-25.
19. Katzan IL, Furlan AJ, Lloyd LE et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the cleveland area experience. JAMA 2000; 283:1151-8.
20. Chiu D, Krieger D, Villar-Cordova C et al. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke 1998; 29:18-22.
21. Albers GW, Olivot JM. Intravenous alteplase for ischaemic stroke. Lancet 2007; 369:249-50.
22. Hoffman JR. Thrombolytic therapy for acute ischemic stroke - tissue plasminogen activator for acute ischemic stroke: is the CAEP position statement too negative? CJEM 2001; 3:183-5.
23. Marler JR, Tilley BC, Lu M et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000; 55:1649-55.
24. Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276 g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic Therapy in Acute Ischemic Stroke Study Investigators. Stroke 2000; 31:811-6.
25. Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 h after acute ischemic stroke: a metaanalysis. Stroke 2009; 40:2438-41.
26. Haley EC Jr, Levy DE, Brott TG et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 min from onset. Stroke 1992; 23:641-5.
27. Schlaug G, Benfield A, Baird AE et al. The ischemic penumbra: operationally defined by diffusion and perfusion MRI. Neurology 1999; 53:1528-37.